Research programme: small molecule therapeutics - Snowdon

Drug Profile

Research programme: small molecule therapeutics - Snowdon

Alternative Names: SND-121; SND-159; SND-226

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Snowdon
  • Developer Snowdon; University of Chicago Pritzker School of Medicine; University of Medicine & Dentistry of New Jersey
  • Class Analgesics; Small molecules
  • Mechanism of Action Glutamate receptor modulators; Glutamate-release-inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Neurological disorders; Neuropathic pain; Toxoplasmosis; Tuberculosis

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Neurological-disorders in USA
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Neuropathic-pain in USA (PO)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Toxoplasmosis in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top